Ramucirumab (anti-VEGFR)

Cat. No.: HY-P9920A Purity: 99.36%: FAQs
Data Sheet SDS COA

Molarity Calculator

Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor.

For research use only. We do not sell to patients.

CAS No. : 947687-13-0

Size	Price	Stock	Quantity
1 mg	USD 260	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 650	In-stock	Estimated Time of Arrival: December 31
10 mg		Get quote
50 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All VEGFR Isoform Specific Products:

View All Isoforms

VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

Biological Activity
Purity & Documentation
References
Customer Review

Description	Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor^[1]^[2].
Isotype	Human IgG1 kappa
Recommend Isotype Controls	Human IgG1 kappa, Isotype Control
Species	Human
In Vitro	Ramucirumab (10 μg/mL) impedes both VEGF- and tumor-driven cord formation^[3]. Ramucirumab does not cross react with mouse VEGFR2^[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Ramucirumab (anti-VEGFR) Related Antibodies
CAS No.	947687-13-0
Appearance	Liquid
Color	Colorless to light yellow
SMILES	[Ramucirumab (anti-VEGFR)]
Shipping	Shipping with dry ice.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Format	Human IgG1 kappa
Biological Activity	Flow cytometry analysis of VEGFR2 overexpression HEK293 cells labelling VEGFR2 with Ramucirumab at 200 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
Purity & Documentation	Purity: 99.36% Select Batch: Data Sheet (256 KB) SDS (251 KB) COA (231 KB) Inhibitory Antibodies User Guide (602 KB)
References	[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53. [Content Brief] [2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5. [Content Brief] [3]. Lowery CD, et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget. 2019 Sep 17;10(53):5523-5533. [Content Brief]